| Bruna, Riccardo |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 49 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C) | Fondazione Italiana Linfomi - ETS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 04/26 | 04/29 | | |
| Recruiting | 2 | 244 | Europe, Canada, US, RoW | Selinexor, KPT-330 | Karyopharm Therapeutics Inc | Diffuse Large B-cell Lymphoma | 04/27 | 11/27 | | |
|
|
|
|
|
|
|
|
|
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Withdrawn | 2 | 150 | Europe | R-DHAP, Pola-R-DHAP | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | 01/29 | 01/29 | | |
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context |
|
|
| Recruiting | N/A | 65 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Castleman Disease | 01/25 | 01/25 | | |
| Not yet recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia | Plasmablastic Lymphoma | 02/28 | 02/28 | | |
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors |
|
|
| Recruiting | N/A | 552 | Europe | Lifestyles Implemented-Survivorship Care Plan (LS-SCP) | Fondazione Italiana Linfomi - ETS | Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | 02/26 | 02/26 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
